[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-bladder-neurogenic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-bladder-neurogenic":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,86,111,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100541933","nxt-post-market-clinical-follow-up-100541933",false,"NCT06336304","NXT Post-Market Clinical Follow-up","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation","Inclusion Criteria:\n\n* Patients medically indicated for urodynamic study\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n\nExclusion Criteria:\n\n* Patients or legally authorized representative with cognitive or psychiatric condition that interferes with or precludes direct and accurate communication regarding the study, giving informed consent or ability to complete the patient questionnaire\n* Patients with confirmed active bladder infections (not including patients with asymptotic bacteria)\n* Pregnant women\n* Patients with recent (less than 2 weeks) pelvic floor surgery\n* Requires use of suprapubic catheter","ALL",{"count":18,"type":19},180,"ESTIMATED","OBSERVATIONAL","NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations",[23,24,25,26,27],"Urinary Incontinence","Urinary Obstruction","Urinary Bladder, Overactive","Urinary Bladder, Neurogenic","Urinary Incontinence, Urge","RECRUITING","2026-05-13",{"date":31,"type":32},"2026-05-15","ACTUAL",{"date":34,"type":32},"2024-06-18",{"date":36,"type":19},"2027-03",{"name":38,"class":39},"Laborie Medical Technologies Inc.","INDUSTRY",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100622722","phase-4-a-randomized-placebo-controlled-trial-of-nitrous-oxide-during-in-office-bladder-botox-injections-100622722","NCT07387315","A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections","A Randomized, Placebo Controlled Trial of Nitrous Oxide\u002FOxygen Plus Standard Care Versus Standard Care Alone During In-office Intradetrusor onabotulinumtoxinA (Botox) Injections","Inclusion Criteria:\n\n* Adult women ≥18 years old scheduled for in-office intradetrusor botulinum toxin injection and able to consent.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected vitamin B12 or folate deficiency or high-risk state (e.g., pernicious anemia, malabsorption, post-bariatric or strict vegan without supplementation)\n* currently pregnant\n* severe\u002Funstable pulmonary disease or baseline hypoxemia requiring supplemental home oxygen\n* eye or ear surgery in the last six weeks\n* trapped-air conditions (e.g., untreated pneumothorax, bowel obstruction)\n* severe active otitis\u002Fsinus disease\n* inability to follow directions\n* history of adverse reaction to nitrous oxide","FEMALE","18 Years",{"count":50,"type":19},96,"INTERVENTIONAL",[53],"PHASE4","The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure?\n\nResearchers will compare a 50:50 nitrous oxide\u002Foxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain.\n\nParticipants will:\n\n* Receive their bladder Botox injection in the office setting\n* Either use nitrous oxide\u002Foxygen plus standard care during the procedure, or sham mask plus standard care\n* Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure",[56,57,58,59,23,25,26,60,27,61],"Overactive Bladder","Neurogenic Bladder","Urge Incontinence","Pain","Urinary Bladder Neurogenesis","Pelvic Floor Disorders",[56,23,58,63,64,65,66,67,68,69,70,71,72,73],"Intradetrusor Injection","OnabotulinumtoxinA","Botox","Bladder Botox","Botulinum Toxins, Type A","Pain Management","Analgesia","Nitrous Oxide","Office-based Procedures","Urogynecology","Pelvic Floor Disorder","NOT_YET_RECRUITING","2026-01-28",{"date":77,"type":32},"2026-02-04",{"date":79,"type":19},"2026-02",{"date":81,"type":19},"2026-12",{"name":83,"class":84},"TriHealth Inc.","OTHER",2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":110},"100450130","feasibility-of-triggered-sacral-neuromodulation-for-neurogenic-bladder-100450130","NCT05141487","Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder","Triggered Sacral Neuromodulation to Treat Neurogenic Detrusor Overactivity Based on Algorithmic Classification of Bladder Filling Status From Wireless Pressure Data","Inclusion Criteria:\n\n* Diagnosis of neurogenic lower urinary tract dysfunction consistent with International Continence Society definition which includes all bladder\u002Furinary sphincter dysfunction related to any neurological disease or injury\n* Male or female\n* If SCI, time from injury \\> 6 months to allow for recovery from the acute phase\n* Can tolerate lying prone \\> 1 hour\n* Functional bladder capacity \\> 100 mL confirmed by urodynamics examination\n* Low risk of upper urinary tract deterioration\n* Over 18 years of age, able to speak and understand English, capacity for consent\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Chronic indwelling or suprapubic catheter usage\n* Severe or rapidly progressive neurologic disease\n* Abnormal sacral anatomy\n* Anticipated need for MRI of body parts below the head\n* Pelvic organ prolapse beyond the hymen\n* Pregnancy\n* Treatment with Botox injection within last six months\n* Current treatment with percutaneous tibial nerve stimulation or other forms of neuromodulation\n* History of sacral neuromodulation treatment or presence of sacral neuromodulation leads or implant\n* Interstitial cystitis\u002Fbladder pain syndrome\n* Benign prostatic hyperplasia preventing catheterization to empty\n* History of anatomically relevant pelvic or anti-incontinence surgery",{"count":94,"type":19},16,"Incontinence associates with military service and post-traumatic stress disorder in both male and female Veterans. Neurogenic detrusor overactivity (NDO) is caused by spinal cord injury or disorder, or peripheral neurodegenerative conditions, and causes urine leakage at low volumes. NDO is disproportionately experienced by Veterans and treatment effectiveness varies greatly between individuals. This project will demonstrate the feasibility of a new type of nerve stimulation-triggered sacral neuromodulation-to treat NDO in Veterans. A wireless bladder sensor will be inserted into the bladder to transmit a feedback signal enabling stimulation from a percutaneous lead. The wireless sensor will also measure NDO symptoms during simulated activities of daily living without catheters. Catheter-free detection of bladder activity will improve the outcomes of neuromodulation evaluations for Veterans with NDO. Future work could use the triggered neuromodulation system to study other methods of nerve stimulation to treat bladder, bowel, or sexual dysfunction.",[23,26],[26,98,99],"Electric Stimulation","Transcutaneous Electric Nerve Stimulation","2026-01-13",{"date":102,"type":32},"2026-01-15",{"date":104,"type":32},"2022-10-03",{"date":106,"type":19},"2026-10-30",{"name":108,"class":109},"VA Office of Research and Development","FED",1,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":51,"phases":121,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":135,"locationsCount":110},"100372385","measurement-of-bladder-pressure-with-a-novel-external-device-cystomanometer---home-use-100372385","NCT04128709","Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use","Inclusion Criteria:\n\n* must have diagnosed neurogenic bladder\n\nExclusion Criteria:\n\n* None","1 Year","99 Years",{"count":120,"type":19},50,[122],"NA","The investigators have developed a novel pressure monitoring device that hooks to standard urinary catheters that are used by patients with a neurogenic bladder on daily clean intermittent catheterization. The device has already been demonstrated to be accurate compared to the gold standard in clinic urodynamics. This study will assess the patients and care givers ability and experience using the device in a home setting.",[26],[126,127,128],"urodynamics","neurogenic","bladder","2025-12-18",{"date":131,"type":32},"2025-12-22",{"date":133,"type":32},"2019-11-19",{"date":81,"type":19},{"name":136,"class":84},"Christopher Cooper",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":51,"phases":146,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":110},"100591267","effect-of-urethral-balloon-dilatation-on-urinary-retention-after-spinal-cord-injury-100591267","NCT06978205","Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury","Inclusion Criteria:\n\n1. Age between 18-80 years old\n2. There is a confirmed diagnosis report of CT or MRI imaging, with the first diagnosis being spinal cord injury (complete or incomplete), which conforms to the International Classification of Spinal Cord Injury Neurology published by the American Spinal Injury Association (ASIA) in 2013\n3. The spinal shock period has passed, and consciousness is clear with stable vital signs\n4. In line with the diagnostic criteria of urinary retention and in combination with clinical practice: the patient can urinate autonomously before spinal cord injury, which is confirmed as spinal cord injury by clinical examination. It is manifested as retention of urine after spinal cord injury, swelling of lower abdomen, filling of bladder, dullness on percussion, residual urine volume of bladder B ultrasonic examination is more than 300ml, which shows that urination is laborious\n5. Urodynamic examination shows maximum urethral pressure greater than 50cmH2O\n6. No tumors or benign prostatic hyperplasia were found\n7. Patients who have had their indwelling urinary catheter removed\n8. Voluntary participation in research and signing of informed consent form\n\nExclusion Criteria:\n\n1. Patients with severe heart, brain, lung and other important organ diseases or mental and cognitive disorders\n2. Individuals with disrupted water electrolyte and acid-base balance\n3. There are serious kidney diseases, bladder fistula surgery, anterior urethral sphincterotomy and other diseases\n4. There is a urinary system infection","80 Years",{"count":145,"type":19},74,[122],"Trial Objectives: This clinical trial aims to explore whether ultrasound - guided urethral balloon dilation can effectively improve the micturition function of patients with urinary retention after spinal cord injury, and to evaluate the safety of this treatment method. The main questions it attempts to answer are:\n\nCan ultrasound - guided urethral balloon dilation reduce the residual urine volume and improve the quality of life of patients with urinary retention after spinal cord injury? Trial Design: Researchers will compare the group receiving ultrasound - guided urethral balloon dilation combined with conventional rehabilitation therapy (the experimental group) with the group receiving only conventional rehabilitation therapy (the control group) to determine the therapeutic effect of ultrasound - guided urethral balloon dilation on urinary retention after spinal cord injury.\n\nTasks for Participants:\n\nParticipants in the experimental group will receive ultrasound - guided urethral balloon dilation and cooperate with conventional rehabilitation therapy (including acupuncture therapy, pelvic floor biofeedback electrical stimulation, and pelvic floor function training). Participants in the control group will receive only conventional rehabilitation therapy for a period of 1 - 2 weeks.\n\nDuring the intervention, patients are required to strictly record a micturition diary under the guidance of researchers or medical staff. The diary should cover details such as daily spontaneous urine output, daily catheterized urine output, daily urine leakage volume, and daily frequency of catheterization.\n\nResidual urine volume will be detected every day for three days before the intervention and three days after the intervention.",[149,26,150],"Spinal Cord Injuries (SCI)","Urinary Retention",[152,153,154,155,156,157],"Spinal Cord Injuries","neurogenic bladder","urinary retention","Urethral balloon dilation","zelen design","Randomized controlled clinical trial","2025-05-10",{"date":160,"type":32},"2025-05-18",{"date":162,"type":32},"2025-04-28",{"date":164,"type":19},"2026-05-01",{"name":166,"class":84},"Qilu Hospital of Shandong University","Urinary Bladder Neurogenic"]